PL2900230T3 - Związki do leczenia otyłości i sposoby ich zastosowania - Google Patents

Związki do leczenia otyłości i sposoby ich zastosowania

Info

Publication number
PL2900230T3
PL2900230T3 PL13773562T PL13773562T PL2900230T3 PL 2900230 T3 PL2900230 T3 PL 2900230T3 PL 13773562 T PL13773562 T PL 13773562T PL 13773562 T PL13773562 T PL 13773562T PL 2900230 T3 PL2900230 T3 PL 2900230T3
Authority
PL
Poland
Prior art keywords
obesity
compounds
treatment
methods
Prior art date
Application number
PL13773562T
Other languages
English (en)
Inventor
Umut Ozcan
Joseph MAJZOUB
Ralph Mazitschek
Isin CAKIR
Serkan CABI
Original Assignee
The Children's Medical Center Corporation
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2900230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Children's Medical Center Corporation, The General Hospital Corporation filed Critical The Children's Medical Center Corporation
Publication of PL2900230T3 publication Critical patent/PL2900230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL13773562T 2012-09-27 2013-09-26 Związki do leczenia otyłości i sposoby ich zastosowania PL2900230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof
EP13773562.7A EP2900230B1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2900230T3 true PL2900230T3 (pl) 2019-02-28

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13773562T PL2900230T3 (pl) 2012-09-27 2013-09-26 Związki do leczenia otyłości i sposoby ich zastosowania

Country Status (21)

Country Link
US (5) US9968575B2 (pl)
EP (3) EP4082541A1 (pl)
JP (2) JP6480864B2 (pl)
CN (3) CN111529535A (pl)
AU (3) AU2013323528B2 (pl)
BR (1) BR112015006848A2 (pl)
CA (2) CA3030272C (pl)
CY (1) CY1121166T1 (pl)
DK (1) DK2900230T3 (pl)
ES (1) ES2696626T3 (pl)
HK (1) HK1213190A1 (pl)
HR (1) HRP20181879T1 (pl)
HU (1) HUE040496T2 (pl)
LT (1) LT2900230T (pl)
PL (1) PL2900230T3 (pl)
PT (1) PT2900230T (pl)
RS (1) RS58010B1 (pl)
RU (2) RU2650646C2 (pl)
SI (1) SI2900230T1 (pl)
TR (1) TR201815668T4 (pl)
WO (1) WO2014052583A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2900230T (pt) 2012-09-27 2018-11-26 Massachusetts Gen Hospital Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
AU2015235979B2 (en) * 2014-03-26 2019-05-02 The Children’s Medical Center Corporation Celastrol and derivatives for the treatment of obesity
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
US10662218B2 (en) * 2015-10-23 2020-05-26 Erx Pharmaceuticals, Inc. Analogs of celastrol
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
KR19990028388A (ko) 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
PT866720E (pt) 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
AU4237797A (en) 1996-08-30 1998-03-19 Amgen, Inc. Methods of increasing sensitivity of an individual to OB protein by upregula ting OB protein receptor
EP0956302A1 (en) 1996-09-20 1999-11-17 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP4175668B2 (ja) 1996-12-20 2008-11-05 アムジエン・インコーポレーテツド Ｏｂ融合タンパク質組成物および方法
DE69807679T2 (de) 1997-04-17 2003-07-31 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
HUP0003428A3 (en) 1997-06-06 2001-12-28 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
DE69921486T2 (de) 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
JP2002526780A (ja) 1998-10-02 2002-08-20 アムジエン・インコーポレーテツド レプチン処置に対する素因の決定方法
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ES2257287T3 (es) 1999-02-12 2006-08-01 Amgen Inc. Composiciones de leptina glicosiladas y metodos relacionados.
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
CA2503196C (en) 2002-10-21 2011-08-02 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
WO2005069415A1 (ja) 2004-01-16 2005-07-28 Mitsubishi Materials Corporation 燃料電池用セパレータ、セパレータの製造方法および固体酸化物形燃料電池
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
WO2007043302A1 (ja) 2005-09-30 2007-04-19 Morinaga Milk Industry Co., Ltd. インスリン抵抗性改善剤
CA2779041A1 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP2009530399A (ja) 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Ｅｒストレスに関連する疾病の治療のための化合物及び方法
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ［２，３−ｄ］ピリミジン化合物
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
US20110218143A1 (en) * 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
EP2271213A4 (en) * 2008-02-01 2011-06-29 Scripps Research Inst METHOD FOR THE TREATMENT OF A GRADE SUFFERED BY PROTEIN HOMEOSTASIS
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
JP2013536203A (ja) 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
MX2014014188A (es) 2012-05-25 2015-05-11 Berg Llc Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta.
PT2900230T (pt) 2012-09-27 2018-11-26 Massachusetts Gen Hospital Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
AU2013323528B2 (en) 2016-11-10
LT2900230T (lt) 2019-01-10
RS58010B1 (sr) 2019-02-28
EP2900230B1 (en) 2018-08-15
US9968575B2 (en) 2018-05-15
EP2900230A1 (en) 2015-08-05
HK1213190A1 (zh) 2016-06-30
US20180185314A1 (en) 2018-07-05
AU2018256619A1 (en) 2018-11-22
US20210008019A1 (en) 2021-01-14
PT2900230T (pt) 2018-11-26
CN111529534A (zh) 2020-08-14
US20210275482A1 (en) 2021-09-09
DK2900230T3 (en) 2018-11-12
RU2018112067A (ru) 2019-03-07
RU2650646C2 (ru) 2018-04-16
BR112015006848A2 (pt) 2018-05-22
HUE040496T2 (hu) 2019-03-28
TR201815668T4 (tr) 2018-11-21
US20170304245A1 (en) 2017-10-26
CA3030272A1 (en) 2014-04-03
CA2886393C (en) 2019-02-26
CN104822374A (zh) 2015-08-05
JP2019070052A (ja) 2019-05-09
US20150250753A1 (en) 2015-09-10
AU2013323528A1 (en) 2015-04-09
US9925161B2 (en) 2018-03-27
EP4082541A1 (en) 2022-11-02
RU2768868C2 (ru) 2022-03-25
RU2015115696A (ru) 2016-11-20
CY1121166T1 (el) 2020-05-29
RU2018112067A3 (pl) 2021-06-24
US11045439B2 (en) 2021-06-29
AU2016247206B2 (en) 2018-08-02
JP6480864B2 (ja) 2019-03-13
CA2886393A1 (en) 2014-04-03
SI2900230T1 (sl) 2019-01-31
HRP20181879T1 (hr) 2019-02-08
WO2014052583A1 (en) 2014-04-03
EP3434268B1 (en) 2022-04-20
ES2696626T3 (es) 2019-01-17
CN111529535A (zh) 2020-08-14
JP2015531376A (ja) 2015-11-02
JP6743211B2 (ja) 2020-08-19
AU2016247206A1 (en) 2016-11-10
EP3434268A1 (en) 2019-01-30
US10653654B2 (en) 2020-05-19
CA3030272C (en) 2021-09-28
AU2018256619B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HK1200348A1 (en) Methods and materials for treatment of pompes disease
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
ZA201408055B (en) Compositions and methods for the treatment of local pain
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP2793875A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DIVERTICULOSE
LT2819655T (lt) Modafinilas, skirtas naudoti asmenų, kenčiančių nuo priklausomybės nuo kokaino, gydymui
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-